Showing 1881-1890 of 2105 results for "".
- Phase 3 Trial for Buntanetap for Parkinson Disease Initiatedhttps://practicalneurology.com/news/phase-3-trial-for-buntanetap-for-parkinson-disease-initiated/2469966/A phase 3 trial (NCT05357989) of buntanetap (Annovis Bio, Berwyn, PA) for Parkinson disease (PD) has been okayed by the Food and Drug Administration (FDA). People with early PD (Hoehn & Yahr [
- Response to COVID-19 Vaccines Confirmed in People With Relapsing Multiple Sclerosis Treated With Ozanimodhttps://practicalneurology.com/news/response-to-covid-19-vaccines-confirmed-in-people-with-relapsing-multiple-sclerosis-treated-with-ozanimod/2469955/In the open-label extension of the DAYBREAK (NCT02576717) trial, participants with relapsing multiple sclerosis (RMS) being treated with ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) deve
- First Participant Receives Study Treatment in Clinical Trial for Dementia with Lewy Bodieshttps://practicalneurology.com/news/first-participant-receives-study-treatment-in-clinical-trial-for-dementia-with-lewy-bodies/2469952/The first participant has received a treatment in the phase 2 SHIMMER trial (NCT05225415) evaluating an antagonist of the sigma 2 progesterone receptor (CT1812; Cognition Therapeutics, New York, NY) for potential treatment of dementia
- Vidofludimus Calcium Significantly Reduces Lesions of Multiple Sclerosis With Minimal Side Effectshttps://practicalneurology.com/news/vidofludimus-calcium-significantly-reduces-lesions-of-multiple-sclerosis-with-minimal-side-effects/2469946/As published in Annals of Clinical and Translational Neurology, vidofludimus calcium (VFC) (IMU-838; Immunic Therapeutics, New York, NY) significantly reduced disease activity in relapsing-remitting multiple sclerosis (
- Intranasal Foralumab Provides Neuroimaging and Clinical Improvements in Secondary Progressive Multiple Sclerosishttps://practicalneurology.com/news/intranasal-foralumab-provides-neuroimaging-and-clinical-improvements-in-secondary-progressive-multiple-sclerosis/2469929/In the expanded access program, after 3 months of intranasal foralumab (Tiziana Life Sciences, New York, NY) treatment of secondary progressive multiple sclerosis (SPMS), a second participant showed clinical improvement on Positron Emission Tomography (PET) imaging analysis, neurologic exami
- Risdiplam Treatment of Type 1 Spinal Muscular Atrophy in Infants Has Long-Term Benefithttps://practicalneurology.com/news/risdiplam-treatement-of-type-1-spinal-muscular-atrophy-in-infants-has-long-term-benefit/2469904/New 3-year data from the FIREFISH study (NCT02913482) reinforce long-term efficacy and safety of risdiplam (Evrysdi; Genentech, South San Francisco, CA) for treatment of symptomatic type 1 spinal muscular atrophy (SMA) in infancy. Appr
- Increase in Antioxidants Correlated With Reduced Risk of Dementiahttps://practicalneurology.com/news/increase-in-antioxidants-correlated-with-reduced-risk-of-dementia/2469902/A study found individuals with high levels of the antioxidants lutein, zeaxanthin, and beta-cryptoxanthin in blood were less likely to develop dementia 16 years later compared with people with lower levels. Study participants had antioxidant blood levels measured and were then eva
- Artificial intelligence Digital Pathology Able to Detect Early-Stage Parkinson Diseasehttps://practicalneurology.com/news/artificial-intelligence-digital-pathology-able-to-detect-early-stage-parkinson-disease/2469891/A new artificial intelligence (AI)-enabled digital pathology technology (Morphology Feature Array; PreciseDx, New York, NY) can diagnose Parkinson disease (PD) accurately in individuals before onset of severe symptoms. Using image patches from biopsy samples, the algorithm had 99% sensi
- Phase 2b Trial of Bryostatin-1 for Alzheimer Disease Completes Enrollmenthttps://practicalneurology.com/news/phase-2b-trial-of-bryostatin-1-for-alzheimer-disease-completes-enrollment/2469890/The phase 2b clinical trial (NCT04538066) of bryostatin-1 (Synaptogenix, New York, NY) for individuals with advanced and moderately severe Alzheimer disease (AD) has completed enrollment with 100
- Long-Term Efficacy and Safety of Ganaxolone for Treatment of Cyclin-Dependent Kinase-Like 5 Deficiency Disorder—A Developmental Encephalopathic Epilepsyhttps://practicalneurology.com/news/long-term-efficacy-and-safety-of-ganaxolone-for-treatment-of-cyclin-dependent-kinase-like-5-deficiency-disorder-a-developmental-encephalopathic-epilepsy/2469875/Ganaxolone (Ztalmy; Marinus Pharmaceuticals, Radnor, PA) was recently approved for adjunctive treatment of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in people, age 2 years or more. CDD, which can be diagnosed with a genetic test, is among the developmental